Navigation Links
AMRI Announces Proposed Private Offering of $100 Million Cash Convertible Senior Notes
Date:11/18/2013

ALBANY, N.Y., Nov. 18, 2013 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI) ("AMRI") announced its intention to privately offer $100 million principal amount of cash convertible senior notes due 2018, subject to market and other conditions, to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). AMRI also expects to grant the initial purchasers of the notes an option to purchase up to an additional $15 million principal amount of the notes solely to cover over-allotments, if any.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint-bookrunning managers for the proposed offering.

The interest rate, conversion rate and other terms of the notes will be determined by negotiations among AMRI and the initial purchasers of the notes. When issued, the notes will be unsecured senior obligations of AMRI. AMRI expects to pay interest on the notes semi-annually on May 15 and November 15 of each year, commencing May 15, 2014. The notes will mature on November 15, 2018, unless earlier repurchased or converted into cash in accordance with their terms prior to such date. The notes will be convertible at the option of the holders only in certain circumstances and solely into cash. The notes will not be convertible into AMRI's common stock or any other security under any circumstances. AMRI will not have the right to redeem the notes prior to maturity.

In connection with the pricing of the notes, AMRI intends to enter into privately negotiated cash convertible note hedge transactions with one or more of the initial purchasers of the notes or their respective affiliates (the "option counterparties"). The initial strike price of the cash convertible note hedge transactions is expected to be the same as the initial conversion price of the note
'/>"/>

SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 METTLER TOLEDO’s newly improved XS ... balances as well as a dual range ... the new SmartPan™ weighing pan delivers results up to ... all balances, ergonomic design details mean users no longer ... for long periods in front of the balance. Barbara ...
(Date:10/1/2014)... 1, 2014 Pfanstiehl has announced the ... manufactured in the USA ... been recognized for playing a key role in ... of evidence that media supplementation with mannose can ... glycosylation," according to Dr. Christopher Wilcox , ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
(Date:10/1/2014)... This report analyzes the worldwide ... by the following Product Segments: Proteases, Polymerases, ... segments also analyzed are Pharmaceuticals & Diagnostics, ... provides separate comprehensive analytics for the US, ... Latin America. Annual estimates and forecasts are ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... TRBN ) announced today that its collaboration ... WYE ), has initiated a Phase 1 clinical ... for the treatment of systemic lupus erythematosus (SLE). Based ... also being evaluated in a Phase 1 clinical trial ...
... an economic environment where many healthcare providers are ... patients are thriving with help from InstaMed. ... and platform, Prime Health Network has increased patient ... while also improving the patient experience at each ...
... Cynvec LLC, a privately held biotechnology company focused on ... of the sindbis viral vector, today announced that Frank ... the BIO National Venture Conference in Boston on Wednesday, ... About Cynvec LLC , Cynvec, a privately held ...
Cached Biology Technology:Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 2Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE) 3Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 2Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network 3
(Date:9/30/2014)... environmental scientists and engineers, led by Clemson University ... $5.25 million grant from the U.S. Department of ... make a direct positive impact on South Carolina ... of radioactive contaminants. , "Understanding the scientific and ... environmental aspects of nuclear technologies is imperative if ...
(Date:9/30/2014)... farm runoff in Hawaii is causing tumors in endangered ... study, published Tuesday in the peer-reviewed open-access journal ... up in algae that the turtles eat, promoting the ... internal organs. , Scientists at Duke University, the University ... (NOAA) conducted the study to better understand the causes ...
(Date:9/30/2014)... is available in German . ... behavioural response to risky situations such as exposure to ... now found in a long-term study on different populations ... metabolic rate and ambient temperature. High metabolic rates and ... in these scenarios birds were more likely to approach ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... PA, September 17, 2007 Women and men appear ... Major depressive disorder (MDD) is one of the most ... the most studied. It is already known that ... changes, associated with MDD and most of todays most ...
... (ACS) News Service Weekly press package (PressPac) with reports ... Engineering News. With more than 160,000 members, ACS is ... journal, or the American Chemical Society, as the source ... ARTICLE #1 FOR IMMEDIATE RELEASE New ...
... Nature Genetics on Sunday 16 September 2007 show that common, ... variation in regions that control activity of genes, rather than ... surprising result comes from a study at the Wellcome Trust ... 270 DNA samples collected for the HapMap Project. The authors ...
Cached Biology News:Women more depressed and men more impulsive with reduced serotonin functioning 2American Chemical Society's Weekly PressPac -- Sept. 12, 2007 2American Chemical Society's Weekly PressPac -- Sept. 12, 2007 3American Chemical Society's Weekly PressPac -- Sept. 12, 2007 4American Chemical Society's Weekly PressPac -- Sept. 12, 2007 5American Chemical Society's Weekly PressPac -- Sept. 12, 2007 6American Chemical Society's Weekly PressPac -- Sept. 12, 2007 7American Chemical Society's Weekly PressPac -- Sept. 12, 2007 8The importance of gene regulation for common human disease 2
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
Biology Products: